홈 > 시장보고서 > 의약품 > 당뇨병

시장보고서

상품코드

1290383

세계의 기초 인슐린(지속형 인슐린) 시장(2023-2030년)

Global Basal Insulin (Long-Acting Insulin) Market - 2023-2030

발행일: 2023년 06월 | 리서치사:

DataM Intelligence | 페이지 정보: 영문 195 Pages | 배송안내 : 1-2일 (영업일 기준)

■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

시장 개요

세계의 기초 인슐린(지속형 인슐린) 시장은 2022년 2억 3,480만 달러에 달하며, 2030년에는 최대 3억 3,160만 달러로 성장할 것으로 예상됩니다. 세계의 기초 인슐린(지속형 인슐린) 시장은 예측 기간(2023-2030년) 동안 4.5%의 CAGR을 나타낼 것으로 예상됩니다.

당뇨병 발병률 증가, 유망한 상환 지침, 제품 도입, 제품 승인, 통합, 투자, 제휴, 확장 등 시장 개발이 세계 기초 인슐린(지속형 인슐린) 시장의 성장을 견인하고 있습니다. 이 시장의 주요 업체로는 Novo Nordisk AS, Sanofi Aventis, Biocon 등이 있습니다.

시장 역학

당뇨병 환자 증가로 기초 인슐린(지속형 인슐린) 시장 성장 촉진

당뇨병 환자 증가는 세계 기초 인슐린(지속형 인슐린) 시장의 성장을 주도하고 있습니다. 예를 들어 Access to Medicine Foundation에 따르면 당뇨병은 세계에서 빠르게 증가하여 연간 670만 명이 사망하고 있습니다. 인슐린에 대한 접근은 점점 더 중요한 다국적 건강상의 중요성을 가지고 있습니다. 당뇨병 환자 수는 2030년 6억 4,300만 명, 2045년 7억 8,300만 명에 달할 것으로 예상되며, 인슐린 접근성이 현저하게 불평등한 중저소득 국가(LMICs)에서 가장 빠르게 증가할 것으로 예상됩니다.

다양한 환자 지원 프로그램의 존재는 시장 성장의 기회로 작용할 것
다양한 환자 지원 프로그램의 존재는 향후 몇 년동안 시장에 유망한 성장 기회를 제공할 것입니다. 예를 들어 Lilly Cares Program, Novo Nordisk Patient Assistance Program(PAP) NovoCare, Insulins ValYOU Savings Program, Direct Purchase Program, Insulin Glargine Follow-On Biologic 등이 인슐린 구매 시 저렴한 가격 또는 환급을 제공합니다.

엄격한 규제 당국이 시장 성장을 저해합니다.

인슐린 제품의 개발 및 상용화를 관리하는 엄격한 규제 기관의 존재는 세계 기초 인슐린(지속형 인슐린) 시장의 성장을 둔화시킬 것입니다. 예를 들어 인슐린의 개발 및 상용화를 관리하는 주요 규제 기관으로는 FDA와 EMA가 있습니다. 이러한 요인들은 기초 인슐린(지속형 인슐린) 시장의 성장을 제한하고 있습니다.

COVID-19의 영향 분석

COVID-19 팬데믹과 세계 각국의 봉쇄로 인해 모든 산업 분야의 기업 재무 상황이 영향을 받고 있습니다. 이에 미국 식품의약국(FDA)은 COVID-19 공중보건 비상사태 기간 중 임상시험 참여자의 안전을 보장하고, 임상시험의 무결성 위험을 최소화하기 위한 일반적인 고려사항을 포함한 가이드라인을 발표하여 임상시험 의뢰자와 연구자를 지원했습니다. 가이드라인을 발표했습니다.

러시아·우크라이나 분쟁의 영향 분석

러시아·우크라이나 분쟁은 이 지역의 주요 시장 기업의 부재와 낮은 보급률로 인해 세계 기초 인슐린(지속형 인슐린) 시장에 중간 정도의 영향을 미칠 것으로 추정됩니다. 그러나 러시아군의 침략을 견디면서 우크라이나의 진료소는 사망자 수가 증가하고 의료 비축량이 제한되어 있습니다. 모든 유형의 의약품이 부족하지만 인슐린 비축에 대한 접근이 제한되어 통제되지 않은 당뇨병과 관련된 장애가 증가하고 있습니다. 또한 원자재 수입 및 수출의 영향은 예측 기간 중 세계 기초 인슐린(지속형 인슐린) 시장 성장에 거의 영향을 미치지 않을 것으로 예상됩니다.

Market Overview

The Global Basal Insulin (Long-Acting Insulin) Market reached US$ 234.8 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 331.6 million by 2030. The global basal insulin (long-acting insulin) market is expected to exhibit a CAGR of 4.5% during the forecast period (2023-2030).

The rising incidence of diabetes, promising repayment guidelines, and market developments like product introduction, product authorizations, consolidations, investments, partnerships, and expansion among others are boosting the global basal insulin (long-acting insulin) market growth. The key players in this market include Novo Nordisk AS, Sanofi Aventis, and Biocon among others.

Market Dynamics

An Increase In Diabetes Cases Drives The Growth Of The Basal Insulin (Long-Acting Insulin) Market.

The growing cases of diabetes are driving the global basal insulin (long-acting insulin) market growth. For instance, according to the Access to Medicine Foundation, diabetes increases rapidly globally, inducing 6.7 million deaths annually. Access to insulin is an increasingly critical multinational health importance. The number of individuals with diabetes globally is anticipated to surpass 643 million by 2030, and 783 million by 2045 rising most quickly in low- and middle-income countries (LMICs), where there is stark inequity in access to insulin.

Presence Of Various Patient Assistance Programs Creates Lucrative Opportunities For Market Growth.

The presence of various patient assistance programs presents the market with prospective growth opportunities in the upcoming years. For instance, Lilly Cares Program, Novo Nordisk Patient Assistance Program (PAP) NovoCare, Insulins ValYOU Savings Program, Direct Purchase Program, and Insulin Glargine Follow-On Biologic among others provide low-cost or repayment on insulin purchases.

Stringent Regulatory Authorities Hamper the Growth of the Market.

The presence of stringent regulatory authorities controlling the development and commercialization of insulin products slows the global basal insulin (long-acting insulin) market growth. For instance, the major regulatory authorities controlling the development and commercialization of insulin include the FDA and EMA. Above mentioned factors are limiting the basal insulin (long-acting insulin) market growth.

COVID-19 Impact Analysis

The financial health of companies across all industries has been impacted by the COVID-19 pandemic and lockdown in numerous nations throughout the world. Therefore, for the period of the COVID-19 public health emergency, the U.S. Food and Drug Administration (FDA) issued guidelines that include general considerations to aid sponsors and researchers, ensuring the safety of trial participants, adhering to good clinical practice (GCP), and minimizing risks to trial integrity.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict is estimated to have a moderate impact on the global basal insulin (long-acting insulin) market, owing to the low prevalence and absence of key market players in this region. However, persisting to countenance invasions from Russian armies, Ukrainian clinics are pushed by rising numbers of deaths and limited medical reserves. There are deficiencies across all kinds of medicine, but restricted access to insulin reserves has guided to an uptick in disorders associated with uncontrolled diabetes. Also, the influence of the import and export of raw materials are anticipated to have little influence over the global basal insulin (long-acting insulin) market growth over the forecast period.

Segment Analysis

The global basal insulin (long-acting insulin) market is segmented based on product type, application, distribution channels and region.

Hospital Pharmacies Segment Accounts for 40% of the Market Share.

Owing to the increasing number of hospitals, the availability of investigational developments, and ease of reimbursement, the hospital pharmacies segment is estimated to hold 42.3% of the global market share. For instance, according to the Republic of Estonia Agency of Medicines, in 2022, the total earning of hospital pharmacies was 137 million euros, with an upsurge of 3% in total compared to previous results.

Geographical Analysis

Europe is Estimated to Hold 28.6% of the Market Share Owing to the Growing Diabetes Prevalence in this Region

Owing to the growing prevalence of diabetes in Europe, the region is estimated to hold the second-largest share accounting for 28.6% of the global basal insulin (long-acting insulin) market. For instance, according to the World Health Organization, there are approximately 60 million individuals with diabetes in the European Region, or roughly 10.3% of males and 9.6% of females aged 25 years and above. The preponderance of diabetes is rising among all ages in the European Region, principally because of additions in overweight and obesity, harmful diet, and physical laziness.

Competitive Landscape

The major global players in the basal insulin (long-acting insulin) market include: Novo Nordisk AS, Sanofi Aventis, Biocon, Julphar, Pfizer, Ganli Pharmaceutical Co., Ltd, Mylan, Wockhardt, and Eli Lily among others.

Why Purchase the Report?

To visualize the global basal insulin (long-acting insulin) market segmentation based on product type, application, distribution channels and region, as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of basal insulin (long-acting insulin) market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as Excel consisting of key products of all the major players.

The global basal insulin (long-acting insulin) market report would provide approximately 53 tables, 54 figures and 195 pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Product Type
3.2. Snippet by Application
3.3. Snippet by Distribution Channels
3.4. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Market Developments
  - 4.1.1.2. Growing Prevalence
- 4.1.2. Restraints
  - 4.1.2.1. Side Effect
- 4.1.3. Opportunity
  - 4.1.3.1. Reimbursement
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. By Product Type

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 7.1.2. Market Attractiveness Index, By Product Type
7.2. Lantus *
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Levemir
7.4. Toujeo
7.5. Tresiba
7.6. Basaglar
7.7. Insulin Glargine Biosimilars

8. By Application

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 8.1.2. Market Attractiveness Index, By Application
8.2. Type 1 Diabetes *
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Type 2 Diabetes

9. By Distribution Channels

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
- 9.1.2. Market Attractiveness Index, By Distribution Channels
9.2. Hospital Pharmacies *
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Retail Pharmacies
9.4. Online Pharmacies

10. By Region

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 10.1.2. Market Attractiveness Index, By Region
10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
- 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.2.6.1. The U.S.
  - 10.2.6.2. Canada
  - 10.2.6.3. Mexico
10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
- 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.3.6.1. Germany
  - 10.3.6.2. The U.K.
  - 10.3.6.3. France
  - 10.3.6.4. Spain
  - 10.3.6.5. Italy
  - 10.3.6.6. Rest of Europe
10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
- 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.4.6.1. Brazil
  - 10.4.6.2. Argentina
  - 10.4.6.3. Rest of South America
10.5. Asia-Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
- 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.5.6.1. China
  - 10.5.6.2. India
  - 10.5.6.3. Japan

Australia

10.5.6.4. Rest of Asia-Pacific

10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels

11. Competitive Landscape

11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis

12. Company Profiles

12.1. Novo Nordisk AS*
- 12.1.1. Company Overview
- 12.1.2. Product Portfolio and Description
- 12.1.3. Financial Overview
- 12.1.4. Key Developments
12.2. Sanofi Aventis
12.3. Biocon
12.4. Julphar
12.5. Pfizer
12.6. Ganli Pharmaceutical Co., Ltd
12.7. Mylan
12.8. Wockhardt
12.9. Eli Lily

LIST NOT EXHAUSTIVE

13. Appendix

13.1. About Us and Services
13.2. Contact Us

02-2025-2992
(주말 및 공휴일 제외)

라이선스 / 가격

PDF & Excel (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 4,350

￦ 6,173,000

PDF & Excel (Multiple User License)

PDF 보고서를 동일 사업장에서 7명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 4,850

￦ 6,882,000

PDF & Excel (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 7,850

￦ 11,139,000

※ 부가세 별도